Rayzebio, Inc.
Clinical trials sponsored by Rayzebio, Inc., explained in plain language.
-
New combo therapy targets tough lung cancer
Disease control OngoingThis early-phase study tests a new drug called RYZ101 added to standard chemotherapy and immunotherapy for people with a specific type of advanced small cell lung cancer that has spread. The main goals are to find the best dose and check for side effects. About 21 adults who have…
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New targeted radiation therapy shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis early-stage trial tests a radioactive drug called RYZ101 in people with a specific type of advanced breast cancer (ER+, HER2-) that has not responded to other treatments. The drug targets cancer cells that have a protein called SSTR on their surface. The study aims to find t…
Phase: PHASE1, PHASE2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC